Evogene
EVGN
18 hedge funds and large institutions have $200K invested in Evogene in 2025 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 7 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
29% more funds holding
Funds holding: 14 → 18 (+4)
14% more capital invested
Capital invested by funds: $176K → $200K (+$23.8K)
86% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$36.4K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$26.5K |
| 3 |
FFA
Farther Finance Advisors
San Francisco,
California
|
+$1 |
| 4 |
Russell Investments Group
London,
United Kingdom
|
+$1 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$24.8K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$13K |
| 3 |
Jane Street
New York
|
-$1.73K |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
-$1.29K |
| 5 |
SS
SBI Securities
Tokyo,
Japan
|
-$697 |
EVGN Hedge Fund Activity: Q4 2025 in Review
18 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q4 2025, worth a combined $200K — up 14% from $176K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new EVGN positions and 1 closed out — a net gain of 4 holders — while 1 added to existing stakes and 7 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $36.4K. The largest seller was Morgan Stanley, cutting an estimated $24.8K.
- 18 institutional investors held Evogene (EVGN) as of Q4 2025, up from 14 in Q3 2025.
- Funds reported $200K of Evogene stock for Q4 2025, up 14% quarter-over-quarter.
- 5 funds opened new Evogene positions in Q4 2025 and 1 closed out, a net change of +4 holders.
- The largest Evogene buyer in Q4 2025 was Citadel Advisors, an estimated $36.4K added.
- The largest Evogene seller in Q4 2025 was Morgan Stanley, an estimated $24.8K sold.
Based on aggregated 13F filings for Q4 2025.